key: cord-1032656-bobncdly
authors: Uzunova, Katya; Filipova, Elena; Pavlova, Velichka; Vekov, Toni
title: Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2
date: 2020-08-24
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2020.110668
sha: ca8a64df5cc6d8cd35a50b04e2a4b16d25085e6e
doc_id: 1032656
cord_uid: bobncdly

Coronavirus disease 2019 (COVID-19) is a kind of viral pneumonia with an unusual outbreak in Wuhan, China, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is currently no licensed antiviral treatment available to prevent human CoV infection. The widespread clinical use and existing knowledge on antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine in the treatment of previous epidemic diseases, namely, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), may be helpful in the combat with novel SARS-CoV-2 infection. Recent clinical evidence didn’t confirm the beneficial role of lopinavir/ritonavir and chloroquine/hydroxychloroquine for COVID-19 patients and their use was reassessed. We provide an overview of the current evidence into the mechanisms of action of these available drugs which are repurposed for treatment of the new virus. Available data identifies remdesivir as an adenosine analogue that can target the RNA-dependent RNA polymerase and block viral RNA synthesis. It has been a promising antiviral drug against a wide array of RNA viruses. 3CLpro is a major CoV protease that cleaves the large replicase polyproteins during viral replication and can be targeted by the protease inhibitor lopinavir/ritonavir but the clinical effects are controversial. Chloroquine/Hydroxychloroquine could impair the replication of SARSCoV-2 by multiple mechanisms and their immunomodulatory properties could ameliorate clinical manifestations that are mediated by immune reactions of the host although its beneficial effects are under question and need to be proven at the clinical level. Existing in vitro and in vivo evidence delineate the molecular mechanisms of these drugs in CoV-infected cells. Numerous studies demonstrated the ability of remdesivir to inhibit SARS-CoV-2 replication but future research would be needed to understand the exact mode of action of lopinavir/ritonavir and chloroquine/hydroxychloroquine in SARS-CoV-2 infected cells and to use this knowledge in the treatment of the current COVID-19.

humans have been identified and the novel coronavirus is the seventh one described to date as being responsible for a respiratory infection. SARS-CoV and MERS-CoV and the new SARS-CoV-2 belong to the betacoronavirus family [3, 4, 5, 6] . The coronaviruses have the largest genome (around 30K) among the RNA viruses. SARS-CoV-2 was closely related (from 82.3% to 88% identity) to two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, but it was more distant from SARS-CoV (from 77.2% to 79%) and MERS-CoV (about 50%) [6, 7] . Furthermore, the performed bioinformatic analysis showed that the nucleotide sequence of SARS-CoV-2 is similar to those of other betacoronaviruses with nucleotide identities of ≥ 83.6% [8] .

There are currently no effective, licensed therapies for human coronaviruses (HCoV) infections and existing treatment strategies are generally limited to symptomatic treatment and supportive care [9, 10] . In the absence of a specific treatment for this novel virus, the effort of researchers is focused on understanding and controlling the disease and on preventing and controlling the replication and spread of the virus.

To devise therapeutic strategies to counteract the SARS-CoV-2 infection, numerous potential treatment options are being evaluated in ongoing clinical trials. Many antiviral and immunological treatments being investigated against coronaviruses are summarized by WHO in Landscape analysis of therapeutics as of March 21, 2020. The real-time dashboard of completed, ongoing and planned clinical trials for COVID-19 [11] includes drugs and promising therapies such as remdesevir, lopinavir/ritonavir, hydroxychloroquine, IL-6 inhibitors (tocilizumab and sarilumab), convalescent plasma therapy, stem-cell transfusion, vaccine candidates, traditional Chinese medicines which are of top 15 interventions of the presented network. Among them, remdesivir, an analogue of adenosine, seems to have a more promising future due to proven in vitro and in vivo antiviral efficacy. Till the beginning of June 2020, promising therapies involving lopinavir/ritonavir and chloroquine or hydroxychloroquine were part of treatment guidelines in many countries, but currently they are excluded from COVID-19 treatment protocols because of uncertainty regarding their risks and benefits and it is recommended that they should be used only in the context of clinical trials [12, 13, 14] . In spite of its known in vitro/in vivo efficacy and safety profiles, some trials evaluating these drugs for COVID-19 infection treatment such as SOLIDARITY (WHO), RECOVERY (UK; NTC04381936) and DisCoVeRy (INSERM; NTC04315948) discontinued hydroxychloroquine and lopinavir/ritonavir arms. The interim trial results showed that hydroxychloroquine and lopinavir/ritonavir produced little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Nevertheless, some J o u r n a l P r e -p r o o f countries worldwide continue to recommend chloroquine/hydroxychloroquine as a treatment option [15, 16, 17, 18] .

The existing drugs that target viral proteins (associated with enzymatic activities or blocking viral replication machinery) or host proteins (involved in viral life cycle, regulating the function of the immune system or other cellular processes in host cells) have great potential and are available on the market.

Our review aims to highlight the potential molecular mechanisms of the therapeutic options available for the cure of other health conditions and their repurposing for the treatment of this novel coronavirus SARS-CoV-2.

Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including SARS-CoV and MERS-CoV. GS-5734 was originally developed for the treatment of the Ebola virus disease. GS-5734, the single Sp isomer of the 2ethylbutyl l-alaninate phosphoramidate prodrug, effectively bypasses the rate-limiting first phosphorylation step of the Nuc (nucleoside ribose analogue). The mechanism of action of Nuc requires intracellular anabolism to the active triphosphate metabolite (NTP), which is expected to interfere with the activity of viral RNA-dependent RNA-polymerases (RdRp) [ 

The proteases encoded by most viruses play a crucial role in the viral life cycle. The protease inhibitors (PIs) bind competitively to the substrate site of the viral protease. This enzyme is responsible for the post-translational proteolysis of a polyprotein precursor and the release of functional viral proteins, allowing them to function correctly and individually in replication/transcription and maturation. Inhibition results in the production of immature virus particles [9, 30] . Coronavirus proteases, of which there are two in SARS-CoV (a papain-like cysteine proteinase (PLpro, nsp3) and a 3C-like proteinase (3CLpro or Mpro, nsp5)) and three in several other coronaviruses, cleave the ORF-1 polypeptide as it is translated, enabling the formation of the viral replication complex [31] . The substrate-binding pockets are highly conserved among CoV 3CLpro, suggesting the possibility for a wide-spectrum inhibitor design targeting this region in the 3CLpro of all CoVs. It is postulated that the 3CLpro-inhibiting activity of lopinavir/ritonavir contributes at least partially to its anti-CoV effects [32, 33] . In silico binding studies of the drugs using the identified crystal structure of Mpro and employing the Hex program to conduct the docking of the ligands to the SARS-CoV main proteinase revealed that lopinavir and ritonavir could basically bind to the active site of SARS main proteinase, but the efficacy of lopinavir/ritonavir was predicted to be poor [34] . According to the latest report of the structure of 3CLpro from SARS-CoV2 (PDB code 6LU7) and the available structure of 3CLpro from SARS-CoV (PDB code 1UK4), the two main proteases J o u r n a l P r e -p r o o f differ by only 12 amino acids. Comparing ligand binding free energies for the main proteases has confirmed that good binders for SARS-CoV are, in general, also good binders for SARS-CoV2 3CLpro [35] .

Protease inhibitors -a class of drugs best known for success against HIV -block the final step of virion assembly in the treatment of human immunodeficiency virus infection with proven efficacy [36, 37] . The combination of lopinavir with ritonavir is widely used as a boosted Lopinavir inhibited MERS-CoV and SARS-CoV replication with comparable efficacy (EC50 = 8.0 μM and a maximal protective effect were observed at a dose of 12 μM) [41] . It was previously shown that lopinavir, but not ritonavir, inhibit SARS-CoV chymotrypsin-like (3CL) protease at the concentration of 50 μM [42] . Moreover, it was suggested that lopinavir blocks a postentry step in the MERS-CoV replicative cycle in vitro [41] . The detectable antiviral activities of ribavirin, rimantadine, lopinavir, and baicalin were shown by using the fRhK-4 cell line [43] and in Vero E6 cells infected with SARS-CoV-2 lopinavir inhibit replication with EC50 at 26.1 μM [26].

During the SARS outbreak, treatment with lopinavir in combination with ritonavir, was explored with some success in nonrandomized clinical trials [37, 41] . Patients with SARS-CoV treated with lopinavir/ritonavir showed a progressive decrease of viral load and reduction of the composite adverse outcome at day 21 [44] . Recently, the antiviral activity of remdesivir and IFN-β was found to be superior to that of lopinavir/ritonavir-IFN-β against MERS-CoV in vitro and in vivo [27] .

The efficacy of lopinavir/ritonavir with or without ribavirin is evaluated in SARS-CoV-2 patients under randomized control trials. Currently, it was demonstrated that this combination has no benefits in adult patients with severe Covid-19 [45] . Although protease inhibitors are a common class of medication used in the treatment of HIV-1 infection their efficacy in human coronavirus infections is not convincing. Moreover, several anti-HIV PIs are also known to J o u r n a l P r e -p r o o f influence other intracellular pathways. It was demonstrated that HIV protease inhibitors (indinavir, saquinavir, and lopinavir), independently from any viral infection, can hinder lymphocyte apoptosis by influencing mitochondrial homeostasis. In view of the weak antiviral activity of protease inhibitors, further studies should be done to ascertain whether the clinical benefit could be attributed to their anti-apoptotic rather than their antiviral activity [46, 47] .

Hence, even if the molecular target of lopinavir/ritonavir is the main protease (3CLpro) in SARS-CoV-2 infected cells ( Figure 1 ) there are no biochemical and molecular studies confirming the interaction and associating this with clinical efficacy of the protease inhibitor.

Chloroquine (CHQ) was introduced into clinical practice in 1947 as a prophylactic treatment for malaria. Hydroxychloroquine (HCQ) differs from chloroquine by the presence of a hydroxyl group at the end of the side chain: the N-ethyl substituent is β-hydroxylated.

Currently, CHQ and its hydroxyl form, HCQ, are used as anti-inflammatory agents for the treatment of rheumatoid arthritis, lupus erythematosus, and amoebic hepatitis [48, 49] . In addition, CHQ has been studied as a potent antiviral agent against HIV-1/AIDS [50, 51, 52] , HCoV-229E [53] , SARS-CoV [54, 55] , influenza A H5N1virus [49] , Influenza A and B [56, 57] and many other RNA and DNA viruses [58] . Many recent reports and published studies suggested that CHQ and HCQ were associated with reduced progression of the COVID-19 and decreased duration of the symptoms [59, 60, 61, 62] . There are, in fact, overall more than 200 trials currently underway around the world on its impact either as a prophylactic or treatment for COVID-19. It is noteworthy that the usefulness of hydroxychloroquine and chloroquine is intensively investigated [63] . [65] . Hydroxychloroquine is significantly more potent than CHQ in vitro (EC50 values: 0.72 and 5.47 μM, respectively) and has a lower potential for drug-drug interactions than chloroquine. Pharmacokinetic models demonstrate that hydroxychloroquine sulfate is significantly superior (5 days in advance) to chloroquine phosphate in inhibiting SARS-CoV-249.50 μM for CHQ and HCQ, respectively). Moreover, they suggested that both CHQ and HCQ blocked the transport of SARS-CoV-2 from early endosomes (EEs) to endolysosomes (ELs) and caused noticeable size/morphological changes in EEs and ELs. They surmised that endosome maturation might be blocked at intermediate stages of endocytosis, resulting in failure of further transport of virions to the ultimate releasing site [64] .

Hydroxychloroquine shares the same mechanism of action as chloroquine. Apart from the probable role of CHQ and HCQ as antiviral agents, their mechanisms of action are not fully understood and it was demonstrated that they have multiple effects on mammalian cells [54] .

ACE2 is known to be a cell receptor for SARS-CoV [69] . The high similarities of the amino acid sequences and predicted protein structures of the receptor-binding domain of SARS-CoV-2 and SARS-CoV suggest that SARS-CoV-2 may efficiently use human ACE2 as a receptor for cellular entry and employ the cellular serine protease TMPRSS2 for S protein priming suggested that the primary mechanism by which infection was prevented was the poor affinity of SARS-CoV spike protein to under-glycosylated ACE2 [54] .

In vitro studies with HIV infected cells also identified that inhibition of glycosylation might be a possible mechanism of action of CHQ. CHQ inhibits HIV replication at a postintegration stage, resulting in the production of immature virions [72] . It was demonstrated that the sole mechanism explaining the anti-HIV activity of CHQ was a decrease in the infectivity of the newly produced virus associated with defective production of the heavily glycosylated 2G12 epitope of gp120 [73] . According to in vitro results, the antiretroviral effects of CHQ are J o u r n a l P r e -p r o o f attributable to the inhibition of viral particle glycosylation. These effects appeared to be specific since the CHQ concentrations effective in vitro neither affected any other step in HIV-1 replication nor were cytotoxic [51, 52] . Thus, there is direct evidence that CHQ is an inhibitor of glycosylation of gp120 and these alterations may be responsible for the decreased infectivity of HIV grown in the presence of chloroquine.

When added after the initiation of infection, these drugs might affect the endosome-mediated fusion and subsequent virus replication [54] . SARS-CoV pseudoviruses may enter cells via receptor-dependent, clathrin-and caveolae-independent, pH-sensitive endocytosis, likely through a process involving lipid rafts [74] . A later study, however, suggests that the entry of coronaviruses into the host cells occurs through clathrin-mediated endocytosis. Murine hepatitis virus (MHV), a prototypic member of the CoV family, requires trafficking to lysosomes for proteolytic cleavage at the FP proximal position of its spike (S) protein membrane fusion to occur [75] . Many authors indicated that S protein cleavage is an important step for fusion activity and subsequent internalization of the SARS-CoV virus genome into cells [76, 77, 78] . Adding CHQ prior to infection results to inhibition of endosome maturation and strongly decreased MHV infection and fusion, which was not observed when the drug was added at 2 hpi, indicating that the compound mainly affects MHV entry [75] .

Chloroquine is a weak base that is known to increase the pH of lysosomal [79] and trans-Golgi Autophagy is a lysosome-dependent degradative pathway. CHQ and its analog HCQ are known clinically relevant autophagy inhibitors. CHQ is a weak base that inhibits lysosomal acidification, which prevents the fusion of autophagosomes with lysosomes and subsequent autophagic degradation [79, 84, 85] . Inhibition of autophagy with CHQ stimulates superoxide generation, ubiquitin-conjugated protein accumulation, and apoptosis in a colon cancer xenograft model [86] . CHQ treatment clearly inhibited autophagy in mouse lung and efficiently J o u r n a l P r e -p r o o f ameliorated acute lung injury and dramatically improved the survival rate in mice infected with live avian influenza A H5N1 virus [49] . H5N1 virus-induced autophagic cell death in alveolar epithelial cells through a pathway involving the kinase Akt, the tumor suppressor protein TSC2, and the mammalian target of rapamycin and autophagy-blocking agents might be useful as prophylactics and therapeutics against infection of humans by the H5N1 virus [87] .

Furthermore, Prentice et al suggested that authophagy was induced by the coronavirus mouse hepatitis virus (MHV) and was required for formation of double membrane-bound MHV replication complexes which significantly enhanced the efficiency of replication. Replication of the virus was impaired in ATG5 knockout embryonic stem cells [88] . The same authors also examined the SARS-CoVs and found out similar colocalization of the key viral replication proteins with endogenous LC3, a protein marker for autophagosome [89, 90] . It could be assumed that autophagy inhibitors like CHQ could inhibit virus replication. At present, the exact role of autophagy in CoV infection remains debatable, and there is much evidence suggesting that the endocytic pathway plays a key role in mediating viral entry for many CoVs, including SARS-CoVs, MERS-CoVs and possibly SARS-CoV-2 [90] .

The anti-inflammatory properties of CHQ/HCQ should also be considered. Several studies have suggested that multiple organ failure observed in fatal cases are most likely associated with not only the direct viral infection and destruction of susceptible cells (e.g., endothelial cells) but also the effects of proinflammatory cytokines, chemokines and other mediators released from infected and activated cells such as monocytes and macrophages [91] . The clinical worsening of individuals with SARS in week 2 is apparently unrelated to uncontrolled SARS coronavirus replication but may be related to immunopathological damage [92] . Another study reveals that the presence of viral elements within endothelial cells and the accumulation of inflammatory cells led to endotheliitis in several organs as a direct consequence of viral involvement and to host inflammatory response [93] .

Moreover, CHQ has immunomodulatory effects, suppressing the production/release of tumour necrosis factor-α and interleukin-6, which mediate the inflammatory complications of several viral diseases [83] . Chloroquine/HCQ was reported to inhibit the production of soluble mature TNF in macrophage cell line [94] , inhibit TNF-α receptor in human histocytic U-937 cells [95] , inhibit TNF-α, IFN-γ and IL-6 in peripheral blood mononuclear cells (PBMC) [96] , reduce TNF-α production and lipopolysaccharide (LPS)-induced IL-1β release in human monocytic cells [97] . It is suggested that CHQ exerts anti-inflammatory and immunomodulatory effects predominantly by pretranslational and nonlysosomotropic mechanisms [98] . Chloroquineinduced inhibition of TNF and IL-6 production is not mediated through a lysosomotropic J o u r n a l P r e -p r o o f mechanism, and chloroquine probably acts on TNF secretion by disrupting iron homeostasis [99] . Besides its antiviral activity and due to its suppressive effects on the production/release of TNF-α and interleukin 6, CHQ/HCQ may be effectively used in the treatment of viral infections characterized by symptoms associated with inflammatory processes and/or immunehyperactivation. Anti-inflammatory effects of CHQ remain poorly understood and beside the regulation of pro-inflammatory cytokines, CHQ can also act on the immune system through cell signaling. CHQ inhibits the activation of p38 MAPK in HCoV-229E-infected cells and evokes the activation of ERK independently of infection. These results suggested that CHQ may inhibit CoV replication by suppressing the p38 activation [100] . Additionally, CHQ strongly inhibited phosphorylation of mitogen-activated protein kinase (MAPK) p38, and to a lesser extent c-Jun N-terminal kinase and extracellular signal-regulated kinase ½ [97] .

Chloroquine could also inhibit innate immune responses trough downregulation of TLR9 signaling pathways requiring endocytosis and acidification of endosomes within plasmacytoid dendritic cells (pDCs) [101] and act as novel antagonists to chemokine receptor CXCR4 that suppress pancreatic cancer cell proliferation [102] . On the other hand, another hypothesized mechanism of CHQ is via the inhibition of antigen degradation and improving the crosspresentation efficiency of DCs in vitro. In vivo evidence suggested that a short course of treatment with CHQ followed by a booster dose of a soluble antigen immunization can efficiently enhance human CD8+ T cell responses [103] and single vaccination with inactivated influenza virus combined with chloroquine treatment elicits a higher T cell immunity in mice [104] .

Regulation of NLRP3 inflammasome activation may offer a promising therapeutic approach by inhibiting or slowing down the process of acute respiratory distress syndrome. HCQ is a known NLRP3 inhibitor, and its potential clinical effectiveness is certainly based on the downregulation of IL-1β expression [105] . The major pro-inflammatory cytokine Interleukin-1-beta (IL-1β) is elevated in plasma from hospitalized COVID-19 patients and its associated signaling pathway seems to drive SARS-CoV-2 pathogenicity. IL-1β secretion is primarily initiated by inflammasomes. Therefore, inflammasome inhibitors may provide valuable therapeutic tools for COVID-19 patients by preventing hyperinflammatory syndromes [106] .

At a severe stage of SARS-CoV-2 infection, CHQ and HCQ treatment may be beneficial to reduce massive cytokine release by their anti-inflammatory and immunomodulatory effects [107] .

In summary, the multiple molecular mechanisms of CHQ/HCQ action remain under investigation. The exact mode of action of CHQ/HCQ has not yet been identified in SARS-CoV-2 infected patients, and probably multiple pathways could be involved (Figure 2 ).

The SARS-CoV-2 is the cause of the coronavirus disease 2019 (COVID-19) that has been [7] . Moreover, the receptor-binding domain of SARS-CoV-2, which directly engages the ACE2 receptor for cell entry, was more closely related to those of SARS-CoVs (73.8-74.9% amino acid identity) [6, 7] .

Since the outbreak, researchers have released many agents that could have potential efficacy against COVID-19. There is currently no clinically proven specific antiviral agent available for SARS-CoV-2 infection like SARS-CoV and MERS-CoV. Certain agents like chloroquine, hydroxychloroquine, lopinavir/ritonavir, and remdesivir are being used in ongoing clinical trials all over the world with hopes to further delineate their role in the treatment and prophylaxis of COVID-19. Furthermore, due to their availability and using for decades and proven safety records, it is reasonable to suggest that they may be appropriate for treatment of COVID-19.

Remdesivir, an adenosine analogue with well-studied mechanism of action in CoV infections, can target the RNA-dependent RNA polymerase and block viral RNA synthesis and has been a promising antiviral drug. Antiviral studies in cell culture and animal models, the available human safety data as well as the clear mechanism of action characterize RDV as a direct-acting antiviral.

Since some authors found that lopinavir-ritonavir treatment did not significantly accelerate clinical improvement [45] hence, antiviral effects as an inhibitor of the SARS-CoV main 3CL protease should be further investigated.

Although CHQ and HCQ are well-known drugs for the treatment of patients with rheumatic diseases for many years their exact mechanisms of action are not fully understood. At the molecular level, CHQ and HCQ interfere with lysosomal activity and autophagy, disrupt membrane stability and alter signaling pathways and transcriptional activity. Direct and indirect mechanisms of these drugs inhibit immune activation by reducing Toll-like receptor signaling and cytokine production and enhance CD8+ T cell responses [103, 109] . Evidence of in vitro efficacy at a clinically achievable dose and high tissue concentration as well as preliminary clinical evidence of efficacy, suggested that CHQ/HCQ could be used for antiviral treatment. According to two open-label, non-randomized clinical trials conducted by French researchers, hydroxychloroquine in combination with azithromycin holds the potential for reducing viral load and accelerating recovery of COVID-19 patients [61, 62] . Recently announced interim results from Solidarity trial suggested that hydroxychloroquine and lopinavir/ritonavir provided no additional benefit compared to standard-of-care. Using the antiinflammatory capacity of CHQ/HCQ and boosting the specific antiviral immunity at the early stages of the disease through these agents may prevent progression to the severe phase of the disease [107] . Zn supplement can favour COVID-19 treatment using some of these anti-viral drugs because Zn could be stopping SARS-CoV-2 replication in infected cells, if combined with chloroquine as an ionophore and may boosting immune effects of the drugs [110] .

Nevertheless, it seems that the mechanism of action of these treatment therapies is the same in human CoVs. Future research would be needed to understand the exact mode of acting of these drugs and their potential to achieve efficient and safe control of the SARS-CoV-2 infection. https://asprtracie.hhs.gov/technical-resources/resource/8036/interim-clinical-guidance-foradults-with-suspected-or-confirmed-covid-19-in-bum. 

Coronavirus envelope protein: current knowledge

Potential interventions for novel coronavirus in China: A systematic review

Middle East respiratory syndrome

Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2

Coronavirus Disease-19)

Epidemic and emerging coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome)

A new coronavirus associated with human respiratory disease in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Current progress in antiviral strategies

About Coronavirus Disease 2019: Prevention and Treatment

A real-time dashboard of clinical trials for COVID-19, the

Interim clinical guidance for adults with suspected or confirmed COVID-19 in Belgium

ABC of AIDS Antiretroviral drugs

Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Coronaviruses -drug discovery and therapeutic options

Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs

Inhibition of the main protease 3CLPro of the coronavirus disease 19 via structure-based ligand design and molecular modeling

Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS

Pharmacologic treatment of SARS: Current knowledge and recommendations

lopinavir/ritonavir (Kaletra) in HIV-infected patients

A review of low-dose ritonavir in protease inhibitor combination therapy

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture

Small molecules targeting severe acute respiratory syndrome human coronavirus

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

A Trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors

Clinical management and infection control of SARS: Lessons learned

Chloroquine and its analogs: A new promise of an old drug for effective and safe cancer therapies

Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

The potential place of chloroquine in the treatment of HIV-1-infected patients

Anti-HIV effects of chloroquine inhibition of viral particle glycosylation and synergism with protease inhibitors

New insights into the antiviral effects of chloroquine

Human Coronavirus HCoV-229E enters susceptible cells via the endocytic pathway

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine

In vitro inhibition of human influenza A virus replication by chloroquine

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycinin 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

COVID-19: An update about the Discovery clinical trial

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

Evaluation of immunomodulators, interferons and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in BALB/c mice

In Vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Treatment options for COVID-19: The reality and challenges

Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Inhibition of human immunodeficiency virus infectivity by chloroquine

Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity

SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway

Coronavirus cell entry the endo-lysosomal pathway in a proteolysis-dependent manner

Entry from the cell surface of severe acute respiratory syndrome coronavirus with cleaved S protein as revealed by pseudotype virus bearing cleaved S protein

Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro

Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites

Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages

Acidotropic amines inhibit proteolytic processing of flavivirus prM protein

Chloroquine inhibits the intracellular multiplication of Legionella pneumophila by limiting the availability of iron a potential new mechanism for the therapeutic effect of chloroquine against intracellular pathogens

Changes in function of ironloaded alveolar macrophages after in vivo administration of desferrioxamine and/or chloroquine

Effects of chloroquine on viral infections: an old drug against today's diseases?

Lucanthone is a novel inhibitor of autophagy that induces cathepsin Dmediated apoptosis

Comparison of different autophagic vacuoles with regard to ultrastructure, enzymatic composition, and degradation capacity-formation of crinosomes

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation

Inhibition of autophagy ameliorates acute lung injury caused by avian influenza A H5N1 infection

Coronavirus replication complex formation utilizes components of cellular autophagy

Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins

Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19

Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Endothelial cell infection and endotheliitis in COVID-19

Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages

Chloroquine decreases cell-surface expression of tumor necrosis factor receptors in human histocytic U-937 cells

Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells

Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms

Chloroquine interferes with lipopolysaccharide-induced TNFa gene expression by a nonlysosomotropic mechanism

Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism

Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK

Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells

Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells

Chloroquine enhances human CD8+ T cell in vivo

Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo

Clinical and biological data on the use of hydroxychloroquine against SARS

CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease

The SARS-CoV-2 spike protein primes inflammasome-mediated interleukin-1-beta secretion in COVID-19 patient-derived macrophages

Is hydroxychloroquine beneficial for COVID-19 patients?

Clinical Characteristics of Coronavirus Disease 2019 in China

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Can Zn Be a Critical Element in COVID-19 Treatment?

We are grateful to Lyudmila Koroteeva for language proofreading of the manuscript.